• The study will be a randomised, double blinded, placebo controlled design.
• It will include 2 groups : trial group and placebo group
• Patients in both groups are children on regular hemodialysis
• The patients in the trial group will receive Curcumin capsule 1 gm for 3 months , and the placebo group will receive a placebo capsule for 3 months
• All patients will be evaluated clinically, and laboratory at baseline, at 3 months after end of supplementation.

Inclusion Criteria:

• Male or female pediatric patients with weight of at least 30 kilograms.
• Undergoing regular hemodialysis for at least 6 months.

Exclusion Criteria:

• Bleeding disorders.
• Chronic liver disease.
• Diabetes mellitus.
• Autoimmune diseases.
• Receiving drugs that are contraindicated, or have major interactions with curcumin, and can't be discontinued or replaced.
• Receiving corticosteroids, or immune-suppressants.
• Patients taking any antioxidant supplements including vitamin E, ascorbic acid, omega -3 fatty acid, or L-carnitine within 3 months prior to enrollment in our study.